Yamini Investments Company Ltd is launching a Rights Issue worth Rs 47.32 crore, available for subscription from 27 May 2025 to 23 June 2025. Shareholders will be entitled to 3 Rights equity shares for every 4 fully paid-up equity shares they own as of the record date, 13 May 2025. Each share has a face value of Rs. 1, and the issue price is set at Rs. 1.2 per share.
Stay tuned with us for comprehensive details on the Yamini Investments Company Ltd 2025 Rights Issue, including the issue size, entitlement, payment terms, and more.
Security Name | Yamini Investments Company Ltd. |
Issue Open / Close | May 27, 2025 - June 23, 2025 |
Record Date | May 13, 2025 |
Issue Size (Amount) | ₹47.32 Crores |
Issue Size (Shares) | 39,42,94,800 |
Right Issue Price | ₹1.2 per share |
Face Value | ₹1 per share |
CMP | ₹1.63 |
Renunciation of Rights Entitlements | June 17, 2025 |
Terms of Payment | The Issue Price of Rs. 1.20/- per Equity Share shall be payable at the time of Application. |
Entitlement | 3 Rights Equity Shares for every 4 fully paid-up Equity Shares held on Record Date |
Disclaimer: The Information compiled by CEBPL on a best efforts basis from information CEBPL received from third party vendors is believed to be reliable. The information may contain errors or omissions, and is subject to change without prior or additional notice. CEBPL provides corporate action information that may be of interest or relevance to CEBPL clients. This does not constitute a recommendation or advice by CEBPL, and CEBPL Clients may not rely upon it. CEBPL does not warrant that the information provided is accurate, timely, or complete. CEBPL Clients are urged to verify the information prior to using it in their investing and trading decisions, including, but not limited to, referral to independent financial news resources, company announcements, and regulatory filings or disclosures. "Investments in the securities market are subject to market risks. Read all the related documents carefully before investing". Registration granted by SEBI and certification from NISM in no way guarantee the performance of the intermediary or provide any assurance of returns to investors. Name of Compliance Officer-Prashant Salian Email Id-Prashant.salian@choiceindia.com Contact No: 022-67079999-Ext-2310. Name of Grievance Officer-Deepika Singhvi Id-ig@choiceindia.com, Contact no. 022-67079999-Ext-834. choiceindia.com
Invest in best pharma mutual funds in India for 2020 with Investica. Explore our top recommended pharma mutual funds to start investing today.